Mesoblast’s Ryoncil™ Gains FDA Nod, Redefining Acute GVHD Treatment for Kids
The FDA has approved Ryoncil™, the first mesenchymal stromal cell therapy, to treat acute graft-versus-host disease (GVHD) in children under 12, providing a much-needed option for this challenging condition.
